Ansa Biotechnologies, a Berkeley, Calif.-based DNA synthesis tech service company, raised $7.9m in seed funding.
The round was led by Horizons Ventures, with participation from Mubadala Capital, Humboldt Fund, and additional investors. Combined with a Pre-Seed round raised in December 2018 led by Fifty Years, the company has raised $9.2 to date.
The company intends to use the funds to recruit talent, build out new, state-of-the-art R&D facilities, and establish strategic industrial partnerships.
Led by Daniel Arlow, Ph.D., CEO, Ansa Biotechnologies is building a DNA synthesis service to accelerate synthetic biology research. Its core technology is a novel DNA synthesis method based on enzymes. The approach, developed by the founders at UC Berkeley, uses an engineered template-independent polymerase conjugated to a single nucleoside triphosphate molecule to rapidly build a DNA sequence one base at a time.
FinSMEs
15/09/2020